Breaking News, Trials & Filings

Trials & Filings in Brief: Nov. 18, 2013

AbbVie, ChanRx, Enanta, Gilead, Merck, Sanofi

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Phase II ChanRx posts positive A-Fib data . . . read more Phase III AbbVie, Enanta show HCV results . . . read more Filings Gilead gets EC approval for Vitekta . . . read more Merck’s Noxafil IV gets priority review . . . read more Cancellations Sanofi ends JAK2 development . . . read more...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters